The Gambia

in page functions
[French]
Gambia
Total population (2017) 2,120,418
Birth cohort (2017) 86,486
Surviving Infants (surviving to 1 year per year, 2017) 82,767
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 48/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 69/1000
World Bank Index, IDA (2015) 2.93
Gross Nation Income (per capita US$, 2014) 460
Co-financing group (2017) Initial self-financing
No. of districts/territories (2015) 7

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Gambia

Type of support

Approvals

2001-2021 (US$)
(23 Mar 2017)

Commitments

2001-2021 (US$)
(23 Mar 2017)

Disbursements

2000-2017 (US$)
(23 Mar 2017)

% Disbursed

(23 Mar 2017)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Total $27,639,696 $31,157,616 $26,305,042
Cash Support (CASHSUPP) $195,000 $195,000 $195,000 100%
Health system strengthening (HSS 1) N/A
Health system strengthening (HSS 2) $1,099,106 $4,617,026
HepB mono (NVS) $455,977 $455,977 $455,977 100%
Hib mono (NVS) $410,021 $410,021 $410,021 100%
HPV Demo (NVS) $282,258 $282,258 $282,132 100%
Immunisation services support (ISS) $671,640 $671,640 $614,140 91%
Injection Safety Devices (NVS) $25,500 $25,500 $33,721 132%
Injection safety support (INS) $101,184 $101,184 $101,184 100%
IPV (NVS) $136,745 $136,745 $136,745 100%
Measles (NVS) $139,910 $139,910 $146,142 104%
Measles-Rubella (NVS) $629,937 $629,937 $629,937 100%
Meningitis A - campaign (NVS) $788,739 $788,739 $788,739 100%
Meningitis A - operational costs (OPC) $727,500 $727,500 $727,500 100%
MR - Operational costs (OPC) $521,500 $521,500 $521,500 100%
Penta (NVS) $4,463,492 $4,463,492 $4,400,890 99%
Pneumo (NVS) $9,027,624 $9,027,624 $9,321,424 103%
Product Switch Grant (PSG) $30,000 $30,000 $29,999 100%
Rotavirus (NVS) $3,151,630 $3,151,630 $2,928,058 93%
Tetra DTP-Hib (NVS) $3,675,683 $3,675,683 $3,675,683 100%
Vaccine Introduction Grant (VIG) $1,106,250 $1,106,250 $906,250 82%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Gambia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2015)

Grade of confidence


N/A
DTP3 - Official country estimates (2015) 97%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2012) 89.10%
Household survey: DTP3 coverage for female (2012) 86.20%
Household survey: Last DTP3 survey (2012) 88%
% districts achieving > 80% DTP3 coverage (2015) 100%
% districts achieving < 50% DTP3 coverage (2015) 0%
MCV WHO/UNICEF estimates (2015) 97%

Breakdown of support

Non-vaccine support Vaccine support
11% 89%
$2,945,572 $23,209,464

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Gambia

14 October 2016

Benin LOGIVAC

Africa takes second “step” toward strengthening supply chain management

New Strategic Training Executive Programme opens at Benin’s LOGIVAC+ Centre, 12 months after similar course offered in Rwanda

27 July 2016

First Sudanese child to receive Meningitis A vaccine as part of routine immunization.

Sudan: first to introduce life-saving meningitis A vaccine into routine immunization

Children in Sudan are set to become the first in the Meningitis belt to benefit from the introduction of Meningitis A vaccine into a routine immunization programme.

22 February 2016

Gavi item

Meningitis A nearly eliminated in Africa through vaccination

Joint press release first published by WHO and PATH, joint founders of the Meningitis Vaccine Project.

close icon

modal window here